This “Eosinophilic Esophagitis - Pipeline Insight, 2022” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Eosinophilic Esophagitis- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eosinophilic Esophagitis pipeline landscape is provided which includes the disease overview and Eosinophilic Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Eosinophilic Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic Esophagitis (EoE) occurs as a result of an immunogenic reaction to various antigens which are commonly found in food and air. There is a strong genetic component involved in the pathogenesis of EoE and a high concordance reported for EoE among family members. Study reported that the gene responsible for EoE was TSLP which is located in the 5q22 region of male X chromosome. TSLP stimulates Th2 cells and induces eotaxin-3. The stimulated Th2 cells activate various proinflammatory cytokines such as IL5, IL13, and IL15, which recruit eosinophils. Eotaxin-3 is overexpressed in the esophageal mucosa in EoE patients. Overall, this immunogenic process starts as an allergic response to various environmental antigens, food leads to the inflammation of esophageal mucosa. The other important cytokine involved in the pathogenesis is TGF-B, which is released by eosinophils and mast cells recruited after immune activation.
This segment of the Eosinophilic Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Eosinophilic Esophagitis: Understanding
Eosinophilic Esophagitis: Overview
Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach. Eosinophils can be found in the esophagus in response to various stimuli or antigen. Eosinophilic esophagitis (EoE) is a chronic immune or antigen-mediated process. Clinically, it presents with various esophageal dysfunction, and pathologically, there is mucosal inflammation predominantly with eosinophils, which is confined to the esophagus only."Eosinophilic Esophagitis- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eosinophilic Esophagitis pipeline landscape is provided which includes the disease overview and Eosinophilic Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Eosinophilic Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic Esophagitis (EoE) occurs as a result of an immunogenic reaction to various antigens which are commonly found in food and air. There is a strong genetic component involved in the pathogenesis of EoE and a high concordance reported for EoE among family members. Study reported that the gene responsible for EoE was TSLP which is located in the 5q22 region of male X chromosome. TSLP stimulates Th2 cells and induces eotaxin-3. The stimulated Th2 cells activate various proinflammatory cytokines such as IL5, IL13, and IL15, which recruit eosinophils. Eotaxin-3 is overexpressed in the esophageal mucosa in EoE patients. Overall, this immunogenic process starts as an allergic response to various environmental antigens, food leads to the inflammation of esophageal mucosa. The other important cytokine involved in the pathogenesis is TGF-B, which is released by eosinophils and mast cells recruited after immune activation.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence in Eosinophilic Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve in Eosinophilic Esophagitis.This segment of the Eosinophilic Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Eosinophilic Esophagitis Emerging Drugs
- APT-1011: Ellodi Pharmaceuticals.
Eosinophilic Esophagitis: Therapeutic Assessment
This segment of the report provides insights about the different Eosinophilic Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Eosinophilic Esophagitis
There are approx. 18+ key companies which are developing the therapies for Eosinophilic Esophagitis. The companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi PharmaceuticalsPhases
The report covers around 20+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Molecule Type
Products have been categorized under various Molecule types such as
- Peptide
- Protein
- Propylene glycols
- Cell Therapy
- Product Type
Eosinophilic Esophagitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Eosinophilic Esophagitis therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Eosinophilic Esophagitis drugs.Eosinophilic Esophagitis Report Insights
- Eosinophilic Esophagitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Eosinophilic Esophagitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Eosinophilic Esophagitis drugs?
- How many Eosinophilic Esophagitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eosinophilic Esophagitis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Esophagitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Eosinophilic Esophagitis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- AstraZeneca
- Bristol Myers Squibb
- Ellodi Pharmaceuticals
- Allakos
- EsoCap AG
- Arena Pharmaceuticals
- GlaxoSmithKline
- Landos Biopharma
- Calypso Biotech
- Takeda
- Dr Falk Pharma
- DBV Technologies
- Revolo Biotherapeutics
- EsoCap
- Aqilion
- Serpin Pharma
Key Products
- Benralizumab
- CC-93538
- APT-1011
- AK002
- ESO-101
- Etrasimod
- Mepolizumab
- CALY-002
- BT-11
- TAK-721
- Milk allergy immunotherapy
- IRL201104
- Mometasone
- AQ280
- SP 16
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
Eosinophilic Esophagitis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Eosinophilic Esophagitis Key Products
Eosinophilic Esophagitis- Unmet Needs
Eosinophilic Esophagitis- Market Drivers and Barriers
Eosinophilic Esophagitis- Future Perspectives and Conclusion
Eosinophilic Esophagitis Analyst Views
Eosinophilic Esophagitis Key Companies
AppendixList of Tables
Table 1 Total Products for Eosinophilic Esophagitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Eosinophilic Esophagitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca
- Bristol Myers Squibb
- Ellodi Pharmaceuticals
- Allakos
- EsoCap AG
- Arena Pharmaceuticals
- GlaxoSmithKline
- Landos Biopharma
- Calypso Biotech
- Takeda
- Dr Falk Pharma
- DBV Technologies
- Revolo Biotherapeutics
- EsoCap
- Aqilion
- Serpin Pharma